Last reviewed · How we verify
Versed — Competitive Intelligence Brief
marketed
Benzodiazepine
GABA A receptor alpha-5/beta-2/gamma-2
Neuroscience
Small molecule
Live · refreshed every 30 min
Target snapshot
Versed (Midazolam Hydrochloride) — Takeda Pharmaceutical Company Limited.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Versed TARGET | Midazolam Hydrochloride | Takeda Pharmaceutical Company Limited | marketed | Benzodiazepine | GABA A receptor alpha-5/beta-2/gamma-2 | 1985-01-01 |
| Imovane | ZOPICLONE | Sunovion Pharms Inc | marketed | zopiclone | GABA A receptor alpha-5/beta-2/gamma-2 | 2004-01-01 |
| Byfavo | Byfavo | Chungbuk National University Hospital | marketed | GABA A receptor alpha-2/beta-2/gamma-2, GABA A receptor alpha-3/beta-2/gamma-2, GABA A receptor alpha-5/beta-2/gamma-2 | ||
| Onfi | CLOBAZAM | Lundbeck Pharms Llc | marketed | Benzodiazepine [EPC] | GABA-A receptor alpha-1/beta-2/gamma-2 | 2011-01-01 |
| Romazicon | FLUMAZENIL | marketed | Benzodiazepine Antagonist [EPC] | Gamma-aminobutyric acid receptor subunit alpha-5 | 1991-01-01 | |
| Prosom | ESTAZOLAM | Abbott | marketed | Benzodiazepine [EPC] | GABA-A receptor alpha-1/beta-2/gamma-2 | 1990-01-01 |
| Versed | midazolam | Generic (originally Roche) | marketed | Benzodiazepine (short-acting) | Multidrug resistance protein 1, Cytochrome P450 3A4, GABA A receptor alpha-3/beta-2/gamma-2 | 1985-12-20 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Versed · 9687495 · Formulation · US
- — Versed · 9289432 · Formulation · US
- — Versed · 8217033 · Formulation · US
- — Versed · 8809322 · Formulation · US
- — Versed · 9687495 · Formulation · US
- — Versed · 9289432 · Formulation · US
- — Versed · 8217033 · Formulation · US
- — Versed · 8809322 · Formulation · US
- — Versed · 10966990 · Formulation · US
- — Versed · 10966990 · Formulation · US
- — Onfi · 12403090 · Formulation · US
- — Onfi · 12290597 · Formulation · US
- — Onfi · 11541002 · Formulation · US
Sponsor landscape (Benzodiazepine class)
- Hamad Medical Corporation · 3 drugs in this class
- Lundbeck LLC · 2 drugs in this class
- UCB Biopharma SRL · 2 drugs in this class
- Universitaire Ziekenhuizen KU Leuven · 2 drugs in this class
- Bausch Health · 1 drug in this class
- Centro Medico Nacional La Raza, IMSS · 1 drug in this class
- Assaf-Harofeh Medical Center · 1 drug in this class
- Daegu Catholic University Medical Center · 1 drug in this class
- B.P. Koirala Institute of Health Sciences · 1 drug in this class
- Consorci Sanitari de l'Anoia · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Versed CI watch — RSS
- Versed CI watch — Atom
- Versed CI watch — JSON
- Versed alone — RSS
- Whole Benzodiazepine class — RSS
Cite this brief
Drug Landscape (2026). Versed — Competitive Intelligence Brief. https://druglandscape.com/ci/midazolam-hydrochloride. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab